Our Science
Our Story
News
Connect
Globe Newswire
August 1, 2024
Featured article
Read More
October 11, 2022
Publications
Frontiers in Molecular Medicine
Safety switch optimization enhances antibody-mediated elimination of CAR T cells
READ MORE
DOWNLOAD
June 28, 2022
In The News
GeekWire
Biotech startups join AWS and other partners in open-source project to help design new proteins
February 21, 2022
Fred Hutch Cancer Center
Red Light, Green Light: Precise cell targeting with Co-LOCKR
October 6, 2021
Business Insider
Power players: These 12 young serial founders are building the next generation of biotech startups
May 18, 2021
BioCentury
Lyell spinout Outpace leverages de novo proteins to control cell and gene therapies
April 5, 2021
Forbes
Outpace Bio raises $30 Million to design next generation cell therapies
March 31, 2021
Public Relations
Creating next generation smart cell therapies: Outpace Bio receives $30 million in Series A funding led by ARTIS Ventures and Lyell Immunopharma Inc
PR
March 21, 2021
Endpoints News
A pair of Lyell founders look to shift the cell therapy paradigm — and they've got $30M to get their plan off the ground
1
All
November 5, 2024
Outpace Bio to present new data on programmed CAR T cell candidate OPB-101 at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical Development
With $144M Series B, Outpace Bio beats funding goal for solid tumor cell therapies
synbiobeta
AI-Driven Cell Therapy Pioneer Outpace Bio Raises $144M in Series B Funding
Protein design startup Outpace lands $144M to test treatments that target solid tumors
April 7, 2024
American Association for Cancer Research (AACR)
In vitro modeling of antigen-driven exhaustion in human CAR T cells
August 2, 2023
Seattle startups move into growing science cluster in South Lake Union
July 10, 2023
How AI is changing the way scientists engineer drugs, biosensors, enzymes and more
May 26, 2023
Outpace Bio expands cell therapy R&D, nets research collaborations in Seattle
April 4, 2024
Outpace Bio Announces Multiple Presentations at the 2024 American Association of Cancer Research (AACR) Annual Meeting
October 31, 2023
Outpace Bio to present new data on tumor-restricted IL-12 designed leveraging OutSmart technology to enhance solid tumor T cell therapies at SITC 2023
May 22, 2023
Outpace Bio expands Seattle presence with cell therapy research hub & collaborations with leading experts in protein design & cancer immunotherapy
May 18, 2023
Outpace Bio to present new data on OutSmart™ IL-2/15, a CAR T cell-produced designed cytokine with tumor-localized immune cell activity, at the 2023 annual meeting of the American Society of Gene & Cell Therapy (ASGCT)
American Society for Gene & Cell Therapy (ASGCT)
OutSmart™ IL-2/15: A CAR T Cell-Produced Designed Cytokine with Tumor-Localized Immune Cell Activity
November 7, 2022
Society for Immunotherapy of Cancer (SITC)
Tuning the cell-cell distance via the non-signaling extracellular spacer domain of chimeric antigen receptors is critical for optimal activity
The Outpace Press Kit is designed to help journalists research Outpace. Please contact our communications team if you need more information or to schedule an interview.